Research programme: ras-selective modified adenoviruses - Oncolytics Biotech

Drug Profile

Research programme: ras-selective modified adenoviruses - Oncolytics Biotech

Alternative Names: Ras-selective modified adenoviruses - Oncolytics Biotech

Latest Information Update: 14 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncolytics Biotech; The Catalan Institute of Oncology
  • Developer Oncolytics Biotech
  • Class Viruses
  • Mechanism of Action Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 24 Oct 2008 Pharmacodynamic data from a preclinical study in Malignant melanoma presented at the 20th-EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
  • 29 Sep 2003 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
  • 05 Aug 2003 Preclinical trials in Cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top